Indications
- Control and Prevention of Hemorrhage in Patients with Factor IX Deficiency (Hemophilia B, Christmas Disease) (see Hemophilia B, [[Hemophilia B]])
- Reversal of Coumadin-Associated Coagulopathy (see Coumadin, [[Coumadin]])
- Reversal of Dabigatran-Associated Coagulopathy (see Dabigatran, [[Dabigatran]])
- Reversal of Rivaroxaban-Associated Coagulopathy (see Rivaroxaban, [[Rivaroxaban]]): abstract from rat study is the only data supporting this treatment
Pharmacology
- Content: human plasma derived (lyophilized powder)
- Factor II
- Factor IX
- Factor X
- Low Amounts of Factor VII
Administration
- Dosing: 30 IU/kg IV Push (not to exceed 10 ml/min)
Dose Adjustment
- Hepatic:
- Renal:
Adverse Effects
Allergic/Immunologic Adverse Effects
- Anaphylaxis/Anaphylactoid Reaction (see Anaphylaxis, [[Anaphylaxis]])
Dermatologic Adverse Effects
- Flushing (see Flushing, [[Flushing]])
- Urticaria (see Urticaria-Angioedema, [[Urticaria-Angioedema]])
Gastrointestinal Adverse Effects
- Nausea/Vomiting (see Nausea and Vomiting, [[Nausea and Vomiting]])
Hematologic Adverse Effects
- Thromboembolic Events
- Deep Venous Thrombosis (DVT)/Acute Pulmonary Embolism (PE) (see Deep Venous Thrombosis, [[Deep Venous Thrombosis]] and Acute Pulmonary Embolism, [[Acute Pulmonary Embolism]])
- Ischemic Cerebrovascular Accident (CVA) (see Ischemic Cerebrovascular Accident, [[Ischemic Cerebrovascular Accident]])
Neurologic Adverse Effects
- Headache (see Headache, [[Headache]])
- Lethargy/Somnolence (see Obtundation-Coma, [[Obtundation-Coma]])
- Tingling (see Parasthesias, [[Parasthesias]])
Other Adverse Effects
- Fever (see Fever, [[Fever]])
- Rigors (see Rigors, [[Rigors]])
- Transmission of Infectious Agents: as agent is human plasma-derived, the risk of transmission of infectious agents (including viruses and Creutzfeldt-Jakob disease agent) cannot be completely eliminated
References
- xxxx